Dube Eric M

CEO Eric Dube sold 22,500 shares for ~$989K near 52-week highs after heavy recent gains; prior exits have been poorly timed.

Eric Dube, Travere's CEO, sold shares near the stock's 52-week high following a substantial rally over the recent months. His track record on this specific stock is unfavorable: his two most recent sales in early April were executed before the stock rose significantly over the following quarter, leaving material gains unrealized. While the stock has recovered sharply from its lows and now trades near its peak, Dube's repeated pattern of selling before gains suggests weak judgment in timing exits—or, conversely, that he departed before the rally accelerated further. The company remains unprofitable with significant net losses, adding context to whether this sale reflects concern about valuation or simply portfolio management. This sale stands out primarily because a CEO selling near all-time highs and after the stock has already surged contradicts the classic insider-buying narrative; however, without clear evidence of deteriorating fundamentals or company guidance, the trade appears more ambiguous than alarming.

CEO Dube sells 64,000 shares (64.0K shares) at $41.09 avg for $2.6M; retains 432,886 shares (432.9K shares)

Eric M Dube, Chief Executive Officer of Travere Therapeutics, executed 3 separate sales totaling 64,000 shares for $2,629,975.10 at a blended average price of $41.09. The sales reduced his holdings by 12.9% relative to pre-transaction holdings of 496,886 shares. The timing warrants attention: Dube's prior trades at TVTX show a pattern of sales that have declined post-sale (30-day returns of -10.8%, -14.8%, and -16.5% on recent February sales), yet the company is trading near its 52-week high ($42.13), up 46.1% in 30 days and 44.2% in 90 days. While Travere shows strong near-term fundamentals (revenue of $164,859,000.00 in the latest quarter, annual revenue growth of +110.4%, and P/E of 18.20), the company remains unprofitable on a full-year basis, which carries earnings risk. The CEO's substantial sale at current elevated valuations, combined with his recent prior sells at higher post-sale decline rates, invites scrutiny into whether this reflects planned portfolio management or forward-looking positioning.

CEO Eric M Dube sells 60,000 TVTX shares for $1.9M; stock down 23.0% in 90 days; recent prior sales also in negative territory

Eric M Dube, Chief Executive Officer of Travere Therapeutics, executed 2 separate sales totaling 60,000 shares (60.0K shares) for $1,855,839.18 at an average price of $30.93 on 2026-04-01, reducing his holdings from 492,886 shares to 432,886 shares (a 12.2% reduction). The stock has declined 23.0% over the 90 days prior to this sale and is currently trading at $30.44, down 24.4% from its 52-week high of $40.28. Notably, Dube's prior five trades at TVTX have shown a consistent pattern of negative short-term outcomes: his four most recent sales (2026-01-23 through 2026-02-20) all posted 30-day declines ranging from 1.2% to 16.5%, with none yet measurable at the 90-day horizon. While company fundamentals remain solid—revenue of $164,859,000.00 with annual growth of 110.4%, net income of $25,706,000.00, and a P/E of 13.53—the cumulative pattern of insider sales during a sustained equity decline warrants attention to whether factors driving the stock's descent may be material to ongoing operations.

CEO Eric Dube sells 60,000 TVTX shares at $30.10; stock now $30.88, down 23.3% from 52-week high

Eric Dube, Chief Executive Officer of Travere Therapeutics, sold 60,000 shares (60.0K shares) on 2026-02-20 at $30.10 per share for total value of $1,805,766.00, reducing his holdings from 492,886 shares to 432,886 shares. This sale is part of an active selling pattern: Dube has executed five prior sales at TVTX, including three within the previous three weeks (2026-01-23, 2026-01-27, and 2026-02-03), suggesting consistent share reduction rather than a one-time event. The stock has declined 14.8% over the past 90 days and 23.3% from its 52-week high of $40.28, now trading at $30.88. Despite strong quarterly fundamentals (revenue $164,859,000, net income $25,706,000, and annual revenue growth of +110.4%), the company carries concerning forward guidance signals—the business was unprofitable on a full-year basis despite recent quarterly profitability—which may contextualize the repeated dispositions by the CEO.

CEO Dube sells 100,087 shares ($3.2M) across 2 transactions; stock down 18.5% from 52-week high

Eric M Dube, Chief Executive Officer of Travere Therapeutics, executed 2 separate sales totaling 100,087 shares for $3,230,315.62 on 2026-02-03, reducing his holdings by 18.8% to 432,886 shares post-transaction. The sales occurred at $32.06 and $32.70 per share (blended average $32.28), while the stock is currently trading at $32.84, down 18.5% from its 52-week high of $40.28 and down 16.9% over the past 30 days. Against Dube's cross-ticker track record of 5 prior sells with a 66.67% well-timed rate and positive 90-day average returns, his same-ticker history at TVTX shows 2 of 3 measurable prior sales were well-timed (negative 90-day returns). The company posted $164,859,000.00 in latest-quarter revenue with +60.6% annual growth, yet remains unprofitable on a full-year basis. This high-volume disposal by the CEO warrants investor attention given the sharp price decline and the insider's recent trading pattern at this security.

CEO Eric M Dube sold 60,000 shares of TVTX for $1.8M at $30.09 avg; stock down 25.4% from 52-week high.

Eric M Dube, CEO of Travere Therapeutics, executed 2 separate sales totaling 60,000 shares for $1,805,134.22 on 2026-01-23 and 2026-01-27, reducing his holdings by 12.5% to 419,173 shares post-transaction. The sales occurred at $30.01 and $30.10, near current price of $30.03 but substantially below the 52-week high of $40.28; the stock is down 25.4% from that peak and down 24.2% over the past 30 days. His prior 3 sales at TVTX showed mixed timing: 2 of the 3 prior sells achieved negative 90-day returns (well-timed), though his most recent October 2025 sales each delivered positive 30-day returns of +17.6% and +19.4%. The company posted strong fundamentals—$164.9M quarterly revenue with +60.6% annual growth and $25.7M net income in the latest quarter—yet remains unprofitable on a full-year basis and trades at a $2.7B market cap. The timing and magnitude of this sale, concurrent with a sharp recent stock decline but against a backdrop of operational growth, merit investor scrutiny regarding management's near-term outlook.

CEO Dube sells 120,000 TVTX shares in 2 transactions for $3.6M at $30.32 blended avg, retaining 419.2K shares.

Eric M. Dube, CEO of Travere Therapeutics, executed 2 separate sales totaling 120,000 shares (120.0K shares) for $3,638,432.15 ($3.6M) on 2025-10-28 and 2025-10-29. The sales reduced his holdings by -22.3% versus pre-transaction shares. The stock has appreciated 24.1% over the prior 30 days and 89.7% over 90 days, currently trading at $29.65, just 1.1% below its 52-week high of $29.98. Dube's prior sale at this ticker in February 2025 resulted in a 90d return of +4.7%, indicating the stock rose after that earlier sale. With the company reporting positive quarterly net income of $25,706,000.00 ($25.7M), though unprofitable on a full-year basis, and annual revenue growth of +60.6%, the sale occurs against a backdrop of strong near-term stock momentum and an improving operational trajectory.

TVTX CEO Dube sells 50,691 shares at $20.21 amid -31.5% revenue decline and -$54.8M net loss

CEO Eric M Dube sold 50,691 shares (50.7K shares) at $20.21 on 2025-02-03, reducing holdings by 10.5% to 430,548 shares. The transaction occurs at a time when Travere Therapeutics reports severe operational stress: annual revenue declined 31.5% while the company recorded a net loss of $54.8M in its most recent full fiscal year. The stock has appreciated 11.9% over the prior 30 days and 22.0% over 90 days, now trading at $21.10, near its 52-week high of $21.10. This sale by the company's chief executive during a period of sharply declining revenue and substantial losses warrants attention to the company's path to profitability and whether management's capital allocation decisions reflect internal views on valuation or liquidity needs.